Backed by renowned physicians, researchers, and leading tech VCs, MoldCo created an easy, affordable system for anyone to access Mold Toxicity treatment, in service of a healthier America.

BOSTON, Sept. 18, 2025 /PRNewswire/ — MoldCo, the first clinician-led digital health platform standardizing mold detox as routine preventative care, today announces $8M in seed funding, co-led by Cantos and Collaborative Fund, bringing the company’s total funding to $11M. The new capital will support the expansion of MoldCo’s virtual clinic and advance its mission to address the widespread yet underdiagnosed health crisis of Mold Toxicity. MoldCo is making expert-led care for mold-related illness more affordable, accessible, and outcomes-driven for patients nationwide.

The Invisible Health Crisis Hiding in Half of U.S. Homes

MoldCo, the first digital health platform standardizing mold detox as preventative care, raised $8M in seed funding.

Most physicians do not screen for or treat mold-related illness, despite more than 50% of U.S. households showing signs of mold, water damage, or dampness. As a result, public awareness remains low, widening a gap in care that leaves millions of patients across the country in the dark without a diagnosis or clear path to healing. People who suffer from mold exposure often spend years—and thousands of dollars—searching for explanations and cycling through specialists and misdiagnoses, when a simple screening for Mold Toxicity could have provided them with clarity.

Even when physicians identify mold as the cause, treatment is often prohibitively expensive or difficult to access. Many experience serious long-term symptoms, including Chronic Inflammatory Response Syndrome (CIRS), a debilitating condition triggered by mold exposure and frequently mistaken for chronic fatigue, fibromyalgia, or anxiety.

A Scalable Solution for Mold Toxicity Care

 Instead of enduring debilitating symptoms and waiting months to see a specialist, patients can immediately access expert, evidence-based Mold Toxicity care through MoldCo’s telehealth platform. Treatment averages just $150–$300 per month, far less than fragmented alternatives, which can cost tens of thousands of dollars and are often ineffective due to limited clinical expertise.

“My own journey through the confusing and often dismissive landscape of conventional medicine while battling mold illness was frustrating and isolating,” said Ariana Thacker, MoldCo founder and CEO. “It revealed a critical gap: individuals are suffering because the specialized knowledge needed to recognize and effectively treat these conditions is widely unavailable. MoldCo was born from that experience. By combining specialized clinical expertise with telehealth accessibility, we’re making evidence-based care available to everyone who needs it as quickly as possible, at a fraction of the current cost.”

“The profound impact of environmental factors, like those found in water-damaged buildings, on human health and the immune system has been documented for decades,” stated Dr. Ritchie Shoemaker, a leading physician and foundational researcher in biotoxin illness and CIRS. “The days of simply living with mold & biotoxin-related illness have been replaced by peer-reviewed treatment protocols, developed from nearly 30 years of research and evidence-based care, and now being made accessible through MoldCo.”

How it Works

Through MoldCo’s telehealth platform, patients can gain clarity on their symptoms, access virtual care, and receive treatments delivered to their home in three simple steps. This streamlined, comprehensive approach directly addresses the accessibility barriers inherent in treating Mold Toxicity, providing patients with:

• On-Demand Expert Care: Direct access to MoldCo’s rigorously vetted, certified specialists in Mold Toxicity, eliminating geographic constraints and long wait times.
• Advanced Lab Testing: Specialized biomarker testing from just $99, along with respective educational content.
• Evidence-Based Treatments: Access to prescription-strength binders, targeted peptides, and specific compounded therapies, shipped directly to the patient.
• Integrated Care Navigation: Continuous 24/7 support via dedicated care navigators through MoldCo’s platform, guiding patients through medical protocol and tracking progress seamlessly.

Investor Confidence in a Category-Defining Company

“The sheer scale of the Mold Toxicity crisis, hidden within the walls of our homes and workplaces and deeply impacting human health, represents exactly the kind of systemic, science-driven challenge Cantos exists to address,” stated Amee Kapadia, Partner at Cantos. “Patients have been left navigating a confusing, expensive, and often invalidating system for far too long. MoldCo is not just providing a service; they are building the essential infrastructure for accessible diagnosis and treatment, leveraging technology to bring scientifically validated protocols and expert care directly to those who have been profoundly overlooked. We are convinced they will lead the way in resolving this widespread health challenge.”

Andrew Montgomery, Partner at Collaborative Fund, commented, “We invest in companies creating a fundamentally better future, and MoldCo directly addresses the critical nexus of our living environments and our long-term health. Their intelligent, telehealth-first approach is precisely what’s needed to democratize access to this specialized care and empower individuals to break cycles of chronic illness linked to mold exposure. We’re proud to support their mission.”

What’s Next for MoldCo

In the next year, MoldCo will expand its specialized clinician network across the U.S., further develop its proprietary care technology, scale patient onboarding and support operations, and invest in clinical research collaborations as it continues to increase public and physician awareness of Mold Toxicity. The company aims to standardize mold detox as a crucial part of routine care, making it as common as a physical or dental exam and setting a new standard for the next wave of preventative health.

MoldCo is already offering advanced lab testing in 46 states and providing care in select states, including Florida, Massachusetts, Michigan, Ohio, and Texas. MoldCo will be available to patients nationwide by 2026.

To learn more about MoldCo or apply for care, visit www.moldco.com.

About MoldCo
MoldCo is the first clinician-led digital health platform standardizing mold detox as routine preventative care with affordable on-demand expert care, advanced lab testing, evidence-based treatments, and concierge care support. The company is on a mission to make mold solutions a standard component of full-body health and tackle the widespread, overlooked health crisis of Mold Toxicity. Leading tech VCs, world-renowned physicians, and pioneering researchers support MoldCo’s commitment to establishing mold detox as a crucial part of routine preventative care. Learn more at www.moldco.com.

Media Contact:
Tess Pawlisch
608-333-9788
moldco@needlepr.com

SOURCE MoldCo

Copyright © 2025 Cision US Inc.